Donahue, Richard P., Stranges, Saverio , Rejman, Karol, Rafalson, Lisa B., Dmochowski, Jacek and Trevisan, Maurizio . (2007) Elevated cystatin-C concentration is associated with progression to prediabetes: the Western New York Study. Diabetes Care, Vol.30 . pp. 1724-1729. ISSN 0419-5992

Preview

PDF WRAP_Stranges_Diabetes_Care-2007-Stranges.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (256Kb)

Abstract

OBJECTIVE – We conducted a nested case-control investigation to examine if elevated baseline concentrations of cystatin-C predicted progression from normoglycaemia to prediabetes over 6 years of follow-up from the Western New York Health Study. RESEARCH DESIGN AND METHODS – 1,455 participants from the Western New York Health Study, free of type 2 diabetes and known cardiovascular disease at baseline (1996-2001), were reexamined in 2002-2004. An incident case of prediabetes was defined as one with fasting glucose below 100 mg/dl at the baseline examination and ≥ 100 mg/dl and ≤ 125 mg/dl at the follow-up examination. All cases (n=91) were matched 1:3 to control participants based upon sex, race/ethnicity and year of study enrollment. All controls had fasting glucose levels < 100 mg/dl at both baseline and follow-up examinations. Cystatin-C concentrations and the urinary albumin to creatinine ratio were measured from frozen (-196 Cº) baseline blood and urine samples. Serum creatinine concentrations were available from the baseline examination. RESULTS –Multivariate conditional logistic regression analyses adjusted for age, baseline glucose level, HOMA-IR, body mass index, hypertension, eGFR, cigarette smoking, and alcohol use revealed a significantly increased risk of progression to prediabetes among those with elevated baseline concentrations of cystatin-C (Odds Ratio, 95% CI: 3.04, 1.34, 6.89) (upper quintile vs. the remainder). Results of secondary analyses that considered hs-CRP, IL-6, E-selectin, or sICAM did not alter these results. CONCLUSIONS - These results suggest that early renal impairment indexed with cystatin-C imparted a three-fold excess risk of progression to prediabetes in this study population. Recent evidence from randomized clinical trials (1,2) among people with prediabetes have provided convincing evidence that early intervention can significantly delay or prevent the progression to type 2 diabetes. The identification of those with prediabetes is assuming greater importance (3) especially in light of the fact that approximately 35 million adults aged 40-74 years old in the United States have prediabetes defined as impaired fasting glucose (4). Microalbuminuria occurs frequently in nondiabetic subjects and places them at increased risk for cardiovascular disease (5-7). The mechanisms behind this observation are poorly understood, however. Albuminuria may reflect underlying vascular damage (8), hypertension (9, 10) endothelial dysfunction (11, 12) and/or low-grade inflammation (13). A large percentage of type 2 individuals pass through a period of prediabetes (14) and may experience early renal dysfunction e.g., a glomerular filtration rate (GFR) above 60 ml/minute per 1.73m2. Currently used estimating equations are poor at identifying early renal impairment and better indices are of great interest (15, 16). Recently, several studies have suggested that cystatin-C levels may be a more sensitive marker of early renal impairment than either albuminuria or serum creatinine concentration (17-20). Therefore, a better understanding of a putative role for cystatin-C in the etiology of prediabetes could shed light on the renal/heart disease connection (21). Given the reported superiority of cystatin C over conventional measures of renal function, we hypothesized that cystatin-C would predict progression to prediabetes independent of serum creatinine or estimated GFR. We also investigated the role of intervening mechanisms including hypertension, insulin resistance, endothelial dysfunction and inflammation.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI) Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Diabetes, Cystatins
Journal or Publication Title:	Diabetes Care
Publisher:	American Diabetes Association
ISSN:	0419-5992
Date:	24 April 2007
Volume:	Vol.30
Page Range:	pp. 1724-1729
Identification Number:	10.2337/dc07-0040
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Description:	Version accepted by publisher (post-print, after peer review, before copy-editing).
Related URLs:	http://care.diabetesjournals.org/cgi/con...
References:	1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346;393-403. 2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Llanne-Parikka P, Keinanen-Kiukaanniem S, Laakso M, Louheranta A, Rastas M, Salminen V, Uustiupa M. Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350. 3. Editorial. Targeting people with pre-diabetes. BMJ 325; 403-404;2002. 4. Benjamin SM, Valdez R, Geiss LS, Rolka D, Venkat Narayan KM. Estimated number of adults with prediabetes in the US in 2000. Diabetes Care 2003; 26: 645-649. 5. Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications: an epidemiologic perspective. Diabetes Care 1992;15:1141-1155. 6. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet 2;530-533: 1988. 7. Kuusisto J, Mykkanen L, Pyorala K, Lasskso M. Hyperinsulinemic microalbumiauria: a new risk indicator for coronary heart disease. Circulation 91;831-837: 1995. 8. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetelogia 32;219-226: 1989. 9. Klein R, Llein BEK, Linton KLP, Moss SE. Microalbuminuria in a population-based study of diabetes. Arch Intern Med 152;153-158:1992. 10. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects. Diabetes 47; 793-800: 1998. 11. Stenhower CD, Henry RM, Dekker JM, Nippels G, Heine RJ, Buter LM. Microalbuminuria is associated with impaired brachial artery flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction. The Hoorn Study. Kidney Intl 2004; (Suppl) 92; S42-44. 12. Ochodnicky P, Vettoretti S, Henning RH, Bulkema H, Van Dokkum RP, de Zeew D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol 19;246-258: 2006. 13. Ritz E. Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart 2003:89;963-964. 14. Knowler WC, Narayan KMV, Hanson RI., Nelson RG, Bennett PH. Tuomeilehto J, et al. Preventing non-insulin-dependent diabetes mellitus. Diabetes 1995;44:483-488. 15. Laterza OF, Price CP, Scott MG. Cystatin-C: an improved estimator of glomular filtration rate? Clin Chem 2002;48:699-707. 16. Tan GD, Lewis AV, James TH, Altmann P, Taylor RP, Levy JC. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes. Reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 25:2004-2009; 2002. 17. Wattanakit, K., Coresh, J., Muntner, P., Marsh, J., Folsom, A. R. Cardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction. JACC 48: 1183-1189; 2006. 18. Shlipak, M. G., Katz, R., Sarnak, M. J., Fried, L. F., Newman, A. B., Stehman-Breen, C., Seliger, S. L., Kestenbaum, B., Psaty, B., Tracy, R. P., Siscovick, D. S. Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease. Ann Intern Med 145: 237-246; 2006. 19. Hankey, G. J. Potential New Risk Factors for Ischemic Stroke: What Is Their Potential? Stroke 37: 2181-2188; 2006. 20. Bibbins-Domingo, K., Chertow, G. M., Fried, L. F., Odden, M. C., Newman, A. B., Kritchevsky, S. B., Harris, T. B., Satterfield, S., Cummings, S. R., Shlipak, M. G. Renal Function and Heart Failure Risk in Older Black and White Individuals: The Health, Aging, and Body Composition Study. Arch Intern Med 166: 1396-1402; 2006. 21. Amann, K., Wanner, C., Ritz, E. Cross-Talk between the Kidney and the Cardiovascular System. J Am Soc Nephrol 17: 2112-2119; 2006. 22. Stranges S, Wu T, Dorn JM, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH, Trevisan M. Relationship of alcohol drinking pattern to the risk of hypertension: a population-based study. Hypertension;44:813-819; 2004. 20 23. Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body fat distribution, liver enzymes, and risk of hypertension. Evidence from the Western New York Study. Hypertension 2005; 46: 1-8. 24. Chobanian AV, Bakrisk GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. National Heart Lung and Blood Institute Joint National Committee on Prevention; National High blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572; 2003. 25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: homeostasis model assessment: insulin resistance and β-cell function form fasting glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985. 26. Bakker AJ. Detection of microalbuminuria: receiver operating curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999:22; 307-313 27. Levy AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11: Suppl: 55A. abstract. 28. Levy AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470. 29. Koenig W, Twardella D, Brener, Rothenbacher D. Plasma concentrations of cystatin-C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clinic Chem 2005;51:321-327. 30. Microalbuminuria Collaborative Study Group, United Kingdom: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Br Med J 306:1235-1239;1993. 31. Haffner SM, Stern MP, Gruber MK, et al. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10: 727-731; 1990. 32. Groop L, Ekstrand A, Forsblom C, et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin dependent diabetes mellitus. Diabetologia 36: 642-647; 1993. 33. Mykkanen L, Zaccaro DJ, Wahgenknecht LE, et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes 1998;47:793-800. 34. Shlipak MG, , . Praught MLSarnak MJUpdate on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006; 15(3):270-275. 35. Shiplak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92. 36. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 1998; 21:1686-1690. 37. Feskens EJ, Bowles CH, Kromhout D. Intra- and interindividual variability of glucose tolerance in an elderly population. J Clin Epidemiol 1991;44:947-953. 38. McDonald DW, Fisher GF, Burnham C. Reproducibility of the oral glucose tolerance test. Diabetes 1965;14:473-480. 39. Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 1974;23:449-453. 40. Shiplak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovik DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
URI:	http://wrap.warwick.ac.uk/id/eprint/142

Request changes to a record

Actions (login required)

View Item